You are here: Industry Insights > Novartis

News List

Novartis to acquire Cadent Therapeutics for $770 mn expresspharma
December 18, 2020
Novartis gains full rights to Cadent’s NMDAr allosteric modulator program, pre-clinical programs and clinical stage movement disorder program.
NICE recommends Novartis’ wet AMD drug Beovu pharmatimes
December 16, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ anti-VEGF treatment Beovu (brolucizumab) for routine NHS use in wet age-related degeneration (AMD) patients.
Novartis’ cholesterol med Leqvio wins EU approval pharmatimes
December 15, 2020
Swiss pharma company Novartis’ cholesterol-lowering drug Leqvio (inclisiran) has been granted approval from the European Commission (EC) for the treatment of primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidaemia.
NICE u-turn on Novartis' migraine drug Aimovig pharmatimes
December 15, 2020
In a rare move, NICE has reconsidered its position on Novartis migraine prevention treatment Aimovig (erenumab), now recommending the drug's NHS use in a Final Appraisal Document (FAD) on the back of further analysis submitted by the company.
Novartis’ Kisqali demonstrates nearly five years median OS in metastatic breast cancer pharmaceutical-business-review
December 14, 2020
Novartis announced updated median overall survival (OS) results for Kisqali (ribociclib) in combination with endocrine therapy, marking the longest survival data ever reported in premenopausal women with hormone receptor positive, human epidermal ...
Novartis signs AI ophthalmology pact with RetinAI pharmatimes
December 10, 2020
Novartis has signed a multi-year collaboration agreement with RetinAI to utilise the latter’s IT solutions and artificial intelligence (AI) tools to support multiple projects in ophthalmology and digital health.
Novartis Set to Achieve 100% Renewable Electricity in European Operations americanpharmaceuticalreview
December 07, 2020
Novartis announced the signature of five virtual power purchase agreements (VPPAs), which are expected to collectively add more than 275 megawatts of clean power to the electrical grid.
NICE turns down Novartis' Adakveo pharmatimes
November 30, 2020
Novartis' Adakveo (crizanlizumab) has hit a setback having failed to gain acceptance by the National Institute for Health and Care Excellence (NICE).
Mesoblast signs ARDS therapy development deal with Novartis pharmaceutical-technology
November 25, 2020
Mesoblast and Novartis have signed an exclusive agreement for the development, manufacture and commercialisation of the former’s mesenchymal stromal cell (MSC) product remestemcel-L.
Novartis secures rights to Mesoblast’s remestemcel-L for ARDS pharmatimes
November 23, 2020
Swiss pharma Novartis has inked an exclusive licence and collaboration agreement with Mesoblast to develop remestemcel-L for acute respiratory distress syndrome (ARDS), including COVID-19-associated ARDS.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page